PSMA PET/CT in contemporary prostate cancer management: From initial staging to biochemical recurrence.

Authors

Emmanouil Panagiotidis, George Angelidis, Filippos Koinis, Varvara Valotassiou, Dimitrios Psimadas, Dimitra Tsivaka, Ioannis Tsougos, Athanasios Kotsakis, Panagiotis Georgoulias

Published in

Hellenic journal of nuclear medicine. Volume 29 Suppl. Pages 53-61.

Abstract

Prostate-Specific Membrane Antigen (PSMA) PET/CT has rapidly become the preferred first-line imaging modality for primary staging of unfavourable intermediate-risk, high-risk, and very high-risk prostate cancer, and for restaging at biochemical recurrence. The objective of this review is to provide nuclear medicine physicians with a comprehensive and practical framework for PSMA PET/CT interpretation, structured reporting, and clinical decision integration, with emphasis on primary staging evidence, biochemical recurrence (BCR) detection rates, imaging pitfalls, and the PSMA-RADS reporting system.
A narrative review of published evidence was performed, encompassing landmark randomised controlled trials and guideline documents from the EAU, EANM, and NCCN. Key trials reviewed included proPSMA, OSPREY, PRIMARY, CONDOR, and VISION.
PSMA PET/CT demonstrated diagnostic accuracy (AUC) of 0.92 versus 0.38 for conventional imaging in primary staging (proPSMA). Detection rates in BCR ranged from 38% at PSA <0.2ng/mL to 97% at PSA >2ng/mL. In a phase 3 RCT, ¹⁸F-PSMA-1007 demonstrated superiority over ¹⁸F-Choline (84% vs 69%, OR 2.53, p<0.001).
PSMA PET/CT provides superior staging accuracy, enables detection of recurrence at low PSA levels, guides oligometastasis-directed therapy, and serves as the mandatory gatekeeper for ¹⁷⁷Lu-PSMA-617 theranostic eligibility. Structured reporting using PSMA-RADS and rigorous CT correlation - particularly to exclude unspecific bone uptakes (UBUs) with ¹⁸F-PSMA-1007 - are core professional competencies of the nuclear medicine physician.

PMID:
42472322
Bibliographic data and abstract were imported from PubMed on 19 Jul 2026.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.